Clinical features of cancer-associated retinopathy

Authors: Li Hui,  Yang Lizhu,  Zou Xuan,  Sun Zixi,  Sui Ruifang

DOI: 10.3760/cma.j.issn.2095-0160.2018.10.011
Published 2018-10-10
Cite as Chin J Exp Ophthalmol, 2018,36(10): 786-790.

Abstract

Objective

To analyze the clinical features of cancer-associated retinopathy (CAR).

Methods

The clinical data of 10 patients who diagnosed as CAR during 5 years were retrospectively analyzed.All patients underwent detailed ocular examinations, including electroretinogram (ERG), optical coherence tomography (OCT), visual field (VF) and autofluorescence(AF).

Results

The primary malignancy was lung carcinoma in 3 patients, thymoma in 3 patients, thyroid carcinoma in 1 patients, maxillary sinus tumor in 1 patients, nasopharyngeal carcinoma in 1 patients and rectal cancer in 1 patients.All patients complained progressive visual reducing.Three patients manifested night blindness.The best corrected visual acuity (BCVA)<0.1 was in three eyes, ≤0.1-<0.5 in seven eyes, and ≥0.5 in ten eyes.Patients showed normal fundi or mild abnormality.OCT images showed disorganization and/or loss of the ellipsoid zone in the macular area in 4 patients, and other six patients had only central foveal ellipsoid zone preserved.Eight patients had moderately or severely reduced ffERG, and 2 patients demonstrated electro-negative ERG.Five patients revealed peripheral visual defect.AF images were from normal to low or high AF patches in the posterior pole and mid-peripheral retina.

Conclusions

The clinical manifestations of CAR are varied as common characteristics of progressive visual decrease with or without night blindness, visual field defect and abnormal ffERG recording.

Key words:

Cancer-associated retinopathy; Immune retinopathy; Clinical features

Contributor Information

Li Hui
Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China
Yang Lizhu
Zou Xuan
Sun Zixi
Sui Ruifang
(Read 36 times, 1 visits today)
Updated: September 4, 2019 — 10:42 am